CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...
CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Le Lézard23h
Pluristyx Enables Safer, Universal Cell Therapy Solutions with Newly Issued U.S. Patent for iACT Stealthtm Technology
Pluristyx, the leading provider of innovative induced pluripotent stem cells (iPSC), announces the issuance of the groundbreaking induced Allogeneic Cell Tolerance (iACT Stealthtm) U.S. Patent No. 12, ...